Imej Jiwa Sdn Bhd’s Post

Discover our #HikmaFootprint. For over 30 years, Hikma #Algeria has been supporting healthcare needs of patients in the country with a diversified portfolio of medicines covering eight therapeutic areas to address a wide range of healthcare needs. Operating four manufacturing plants we are investing in building more local capabilities to continue to improve access to essential medicine. We leverage our extensive high-quality manufacturing capabilities to supply medicines and make a meaningful impact in the local communities we serve. Read more: https://lnkd.in/dC7_Dp4B #PharmaceuticalManufacturing #LocalExpertiseGlobalReach #MENA

The growing demand for Biosimilars in Southeast Asia presents a significant opportunity to address healthcare challenges. However, to fully harness their potential, we must also focus on developing a robust regulatory framework to ensure accessibility for all. As we've seen in Europe, Biosimilars offer a pathway to more affordable treatment options, cost savings, and increased access for patients. Now, it's time to extend these benefits to Southeast Asia. By prioritizing the establishment of clear guidelines and approval processes tailored to the region's needs, we can pave the way for Biosimilars to make a meaningful impact on healthcare systems. 🚀 Initiatives like Medicines for Europe's annual BIOS24 meeting demonstrate the power of bringing stakeholders together to drive change. Let's take inspiration from their efforts and work collaboratively to implement sustainable procurement processes and enhance competition in the Southeast Asian market. Together, we can alleviate the healthcare burden, address equity and access issues, and fulfill unmet medical needs in the region. It's time to make Biosimilars more than just a promise—they're a pathway to a healthier, more equitable future for all. #Biosimilars #HealthcareAccess #SoutheastAsia #RegulatoryFramework #HealthEquity #MedicinesForAll #Sandoz #Pioneeringaccessforpatients

While Europe has been the first region to approve and adapt biosimilars, there is still more to be accomplished to democratize access to biologic medicines across the continent. Medicines for Europe’s annual BIOS24 meeting plays a key role in bringing stakeholders who can make a difference together. We believe advancements can be made to:  👉Tailor the clinical development of biosimilars   👉Improve biosimilar guidelines and approval processes  👉Implement sustainable procurement processes that increase competition and secure supply These changes would help keep biosimilars sustainable, which will benefit healthcare systems by providing more affordable treatment options, generating cost savings, and most importantly, granting greater access for patients.    Read more from our experts Isabell Remus, Chair of the Biosimilar medicines sector group at Medicines for Europe & Head Commercial Europe, Sandoz and Martin Schiestl, Global Head Regulatory Affairs Policy, Sandoz.👇 #BIOS24 #Biosimilars #Healthcare https://bit.ly/3JcxZRR

🎉✨ Ring in the New Year with Hope and Innovation! ✨🎉 As you celebrate the closing of 2024 and toast to the promise of 2025, Sen-Jam Pharmaceutical is working tirelessly to deliver breakthroughs that matter. 🍾 Our SJP-001 therapeutic is heading into a critical Phase 2 clinical trial in Australia. With the potential to become the first-ever FDA-approved solution for alcohol hangovers, it tackles the root cause: inflammation. By significantly reducing symptoms and duration, SJP-001 aims to restore productivity and enhance well-being for social drinkers everywhere. We’re not just creating a product—we’re reshaping an industry. From disrupting the $1.48T pharma market to preserving healthspan with a preventative mindset, Sen-Jam is on a mission to redefine modern healthcare. 🌍💡 Here’s to a New Year filled with health, happiness, and groundbreaking progress. 🥂 #Innovation #HangoverRelief #Goodkarmapharma #newyearseve #SenJamPharma

The SMI POWERHOUSE: A Breakthrough in Inhaled Drug Delivery. King’s Lynn, Norfolk, U.K.; Ansbach, Bayern, Deutschland – 10 December 2024. MERXIN Ltd and OECHSLERhealth are excited to announce a Strategic Partnership to Establish The SMI PowerHouse to Streamline Soft Mist Inhaler Access for Drug Developers. Read the announcement here: www.TheSMIPowerHouse.com.

Monique Mantovani shared invaluable insights during the panel session "Key Note: Unveiling the Keys to Local Production in LatAm" at Biosimilars LatAm - Colombia 2024. She emphasized the importance of dialogue with local regulatory agencies like #ANVISA, highlighting how such discussions can streamline the #biosimilar registration process and pave the way for local production. 🌟💬 Let's continue fostering these partnerships to streamline biosimilar registrations and enhance healthcare accessibility. LIBBS FARMACÊUTICA LTDA #BiosimilarsLatAm #Colombia2024 #HealthcareRegulation #CollaborativeEfforts #RegulatoryDialogue #LocalProduction

Rise Together for Pharma Quality Excellence: I Pledge #CommitmenttoQuality It's time for industry leaders to unite, prioritize patient safety, and set new benchmarks in quality standards in pharma. Take the pledge today—because quality isn't just a goal, it's our responsibility. Join the movement! Read the full article here: https://bit.ly/4etTFqv #eminencebusinessmedia #eminencegroupventures #EminenceUnfiltered #EGV

The implementation of the new EU #HTA procedure is currently entering a decisive phase. #MemberStates are drafting and deciding on the detailed rules of the procedure in the “Comitology” Committee on Health Technology Assessment, with the support of the European Commission, which will be laid down in Implementing Acts.   📢 With the other #industry association members of the HTA Stakeholder Network, EUCOPE share serious concerns over the workability of the proposed draft rules, that risk creating an unworkable framework for Joint Clinical Assessments (JCAs) and risk the aim of joint #EU HTA of ensuring better #access for #patients to innovative health technologies.   ❗Unworkable timelines and lack of possibility for early interactions with the assessors mean that especially small to mid-sized companies, that are less resourced, are put under a serious threat of being unable to adequately deliver on their submission and contributing to a #JCA that can fulfil the aim of the Regulation. 👉 Read the joint statement: https://lnkd.in/dDiVT6xv Alliance for Regenerative Medicine, EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, Vaccines Europe

Did you know that generic medicines are created to be the same as branded drugs, use the same active ingredients and have the same effects? Find out more: #EssentialMedicinesList #Generics #WHO #AccesstoMedicines #HealthyCommunities